Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Autofluorescence in Uveitic and Diabetic Macular Edema

This study has suspended participant recruitment.
(Technical issue)
Sponsor:
Information provided by (Responsible Party):
Carsten Heinz, St. Franziskus Hospital
ClinicalTrials.gov Identifier:
NCT00956124
First received: August 10, 2009
Last updated: May 21, 2015
Last verified: May 2015
  Purpose
The aim of this study is to determine whether fundus autofluorescence and macular pigment distribution in inflammatory and diabetic macular edema are altered.

Condition
Uveitis
Macular Edema

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by St. Franziskus Hospital:

Estimated Enrollment: 40
Study Start Date: October 2010
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
uveitic patients
patients with diabetes

Detailed Description:
After macular pigment measuring we will perform fundus autofluorescence, fluorescein angiography and optical coherence tomography. any associations of macular pigment distribution and fundus autofluorescence with macular anatomic features are analyzed. primary outcome measure is the macular pigment distribution in patients with altered fundus autofluorescence. Furthermore we will compare the findings between diabetic and inflammatory edema.
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with uveitis or diabetes
Criteria

Inclusion Criteria:

  • patients with diabetic or uveitis macular edema

Exclusion Criteria:

  • children patients with known allergy to fluorescein
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00956124

Locations
Germany
Department of Ophthalmology at St Franziskus Hospital
Muenster, North-Rhine-Westfalia, Germany, 48145
Sponsors and Collaborators
St. Franziskus Hospital
  More Information

Responsible Party: Carsten Heinz, Head of Department, St. Franziskus Hospital
ClinicalTrials.gov Identifier: NCT00956124     History of Changes
Other Study ID Numbers: 2009-017-f-S 
Study First Received: August 10, 2009
Last Updated: May 21, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Edema
Macular Edema
Uveitis
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Uveal Diseases

ClinicalTrials.gov processed this record on December 05, 2016